rvp-001
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2022 (NCT05413668)
Timeline
Indications
Studied for
- Brain Diseases · Phase 2
- Brain Neoplasms · Phase 2
- Central Nervous System Diseases · Phase 2
- Glioma · Phase 2
- Healthy Volunteers · Phase 1
- Lymphoma · Phase 2
- Meningioma · Phase 2
- Multiple Sclerosis · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neurilemmoma · Phase 2
- Neurofibroma · Phase 2
- Neuroinflammatory Diseases · Phase 2
- Neuroma, Acoustic · Phase 2
- von Hippel-Lindau Disease · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- gadolinium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06322342 | Phase 2 | Mar 15, 2024 | National Cancer Institute (NCI), Reveal Pharmaceuticals Inc. |
| NCT05413668 | Phase 1 | May 18, 2022 | National Cancer Institute (NCI), Quotient, Reveal Pharmaceuticals Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2022 |
| Reveal Pharmaceuticals Inc. | For profit | 2 | 2 | 2 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1